Internet use, in- and exclusion in decision-making processes within political parties

This paper investigates the effect of internet-use on democratic decision-making processes within political parties. Through two case studies of the Green Party and the Pirate Party Germany, the influence of internet-use on these processes and their inclusiveness are shown. We argue that how the internet is used in democratic processes impacts on participation and inclusion.How internet technology interacts with decision making processes within parties depends on the existing party structure and culture. Thus, in order to achieve meaningful and inclusive participation, the institutional framework and the influence it has must be considered in process and tool design. Whereas the affordances of specific online tools have been evaluated, the institutional context in which they are embedded have so far been widely ignored. We offer a structure for analysis of these foundation

Arguing with behavior influence: A model for web-based group decision support systems

In this work, we propose an argumentation-based dialogue model designed for Web-based Group Decision Support Systems, that considers the decision-makers' intentions. The intentions are modeled as behavior styles which allow agents to interact with each other as humans would in face-to-face meetings. In addition, we propose a set of arguments that can be used by the agents to perform and evaluate requests, while considering the agents' behavior style. The inclusion of decision-makers' intentions intends to create a more reliable and realistic process. Our model proved, in different contexts, that higher levels of consensus and satisfaction are achieved when using agents modeled with behavior styles compared to agents without any features to represent the decision-makers' intentions.- (undefined

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of three anti-cancer drugs (fluoropyrimidines: 5-fluorouracil, capecitabine and tegafur) to decrease the risk of severe, potentially fatal, toxicity (such as diarrhoea, hand-foot syndrome, mucositis or myelosuppression). Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) enzyme deficiency increases risk of fluoropyrimidine-induced toxicity. The DPYD-gene activity score, determined by four DPYD variants, predicts DPD activity and can be used to optimize an individual’s starting dose. The gene activity score ranges from 0 (no DPD activity) to 2 (normal DPD activity). In case it is not possible to calculate the gene activity score based on DPYD genotype, we recommend to determine the DPD activity and adjust the initial dose based on available data. For patients initiating 5-fluorouracil or capecitabine: subjects with a gene activity score of 0 are recommended to avoid systemic and cutaneous 5-fluorouracil or capecitabine; subjects with a gene activity score of 1 or 1.5 are recommended to initiate therap